Portfolio Finder

Perora brought REDIA to market, the first effective medical food for the dietary management of diabetes type 2.

Phialogics is an innovative start-up in the field of autoimmune diseases. Founded in 2021 by a team of widely recognized experts in protein engineering and immunology, the company based in Basel (CH) and Heidelberg (GER) is committed to making a decisive contribution to the autoimmune disease space. The founding team is backed by strong Scientific Advisory and Supervisory Boards, which puts the company in a good position to move fast on the lead candidate and develop novel biologics.

Photonics Healthcare enables doctors to monitor cellular oxygen.

PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the practice network creates attractive jobs in poorly supplied regions and helps with its own software solutions for practice administration and patient communication.

PreComb Therapeutics AG is a privately held Swiss biotech company founded in 2018 by Jens M. Kelm, Peter Steiner and Olivier Mauti with the aim of developing technologies that bring precision medicine benefits to all cancer patients. PreComb is pioneering breakthrough technologies to directly test the drug response of individual cancer patients, based on patient-derived 3D microtumors. For the first time, a fully automated point-of-care solution for determining drug sensitivity or resistance directly in the clinic is being developed. This offers the unique ability to routinely test entire portfolios of cancer drugs and drug combinations in large-scale, making the technology a universal tool from drug discovery to guiding therapies.

Predemtec focuses on the research, development and manufacture of innovative diagnostic tests for use in the detection of dementia-related risk factors. The first product, the Predemtec DX test, is a serum-based immunoassay and uses analysis algorithms for the early detection and risk diagnosis of senile dementia (Alzheimer’s type, AD).

PreOmics develops and provides innovative technologies for customers around the world for mass spectrometry (MS) - based proteomics using cutting-edge technologies to support researchers in their protein analysis needs.

Preventicus GmbH is developing smartphone-driven solutions to capture and analyze patients' vital parameters for early preclinical risk screening of lifestyle-related illnesses. Seed funding for the Jena-based company is managed by the German High-Tech Gründerfonds (HTGF) in Bonn and Born2Grow venture fund in Heilbronn. The capital is being provided to develop the products and portal to marketability.

Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system.

Exit since July 2015.

The company was founded in 2022 and is headquartered at the STIMULATE research campus in Magdeburg's “science-harbour”. The scientific company is a spin-off by scientists from the Otto-von-Guericke-University Magdeburg. The foundation of the company was based on a 3-year EXIST research transfer grant from the German Federal Ministry for Economic Affairs and Climate Action (BMWK), which was approved in 2021. The focus of technical development is on both the hardware and software areas of computed tomography scanners.

Reactive Robotics develops adaptive and intelligent therapy robotics which automate early-mobilization in the intensive care unit. Using robotic modules that can be attached and detached on and from the patient bed, patients can be mobilized directly in their hospital bed. As compared to existing solutions, this approach supersedes the time-intensive and dangerous transfer of the patient onto a separate therapy device. The device is scheduled to become available in Europe beginning of 2018.

Refined Laser Systems GmbH, based in Münster, Germany, was founded in 2019 as a spin-off from University of Münster by Max Brinkmann, Tim Hellwig and Christoph Seidenstücker. The company's core expertise is the development of laser and microscopy technology. The company's innovative PICUS DUO and PICUS Q laser systems are used worldwide as key components for SRS microscopy and quantum technology. With the long-term goal of making a meaningful contribution to patient well-being and healthcare, Refined Laser Systems is committed to bringing its technology to clinical applications.

Resolve Biosciences is creating solutions which offer the power of Molecular Cartography enabling scientists to gain valuable insights at subcellular resolution, across vast numbers of biomolecules (RNA, DNA, proteins) to create three-dimensional maps of molecular activity in living cells.

Rigontec GmbH is a preclinical biotech company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Rigontec’s lead compound ImOl100 targets a novel receptor of the innate immune system, Retinoic acid Inducible Gene I (RIG-I).

RIMASYS offers prefractures specimen for educational purposes in the field of orthopedic surgery. The innovative MedTech company is setting new standards in surgical education and implant development through innovative education and validation with life-like fractured human specimen.

SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.

Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.

650 million people suffer from mental illness like depression, anxiety or burnout worldwide. Even in developed countries there is a huge treatment gap: 50% do not get treated. Selfapy offers scientifically proven online psychotherapy courses to make fast and affordable care accessible to everyone. Courses are effective at treating symptoms by combining advanced technology with elements of traditional care.

Senostic is a diagnostics company developing a differential diagnostic test to detect multiple neurodegenerative diseases in a single test based on its proprietary SeedCylcer platform technology.

Sierra Sensors is combining state of the art label-free detection with cutting edge microfluidic sample delivery, sensor design, and automation, to supply researchers with high performance analytical biosensors.

Signatope develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays.

SIGNATOPE (SIGNAture epiTOPE) immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE's immunoassays. The short epitope allows us to establish quantitative assays for the same protein in different species and for isoforms of protein families. Even immunoassays for notoriously difficult proteins like drug transporters can be established while providing the speed and the sensitivity of an antibody-based method.

SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A goal is to develop optimized cell systems for the optimized vaccine, antibody or protein production

Smarterials Technology GmbH is a young MedTech company with high competence in the fields of inorganic chemistry, surface functionalization and process technology. The company was founded by two material scientists and one economist and develops disposable gloves for healthcare workers based on innovative materials. The double-layer gloves are optimized for infection control and tactile sensitivity, provide a dual contamination barrier, and visually indicate perforations from needle punctures. The two-in-one gloves are designed to replace double-cloving, which is practiced primarily during surgeries.

Sonormed is focused on digital medical products and builds the appropriate audiological infrastructure to adress the potential that large numbers of unserviced hearing damages, among them tinnitus, provide worldwide and to open up this market with new technologies.

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.

Tacalyx researches and develops therapeutics targeting TACAs (tumor-associated carbohydrate antigens). These strongly tumor-specific structures are synthesized by cancer cells and contribute significantly to its virulence and metastasis. The recent possibility of synthesizing these complex structures allows the production of specific antibodies for the treatment of currently unsatisfactorily treatable cancers.

Thermosome is a clinical-stage drug development company focused on targeted tumor therapy combined with immune stimulation for improved cancer therapy. At its core is a novel, proprietary tumor targeting approach that allows for significantly increased local drug concentrations and improved tumor penetration to achieve improved clinical treatment efficacy. The lead candidate THE001 is a thermosensitive formulation of doxorubicin being developed in soft tissue sarcoma.

TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the immune system’s defences.

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

VACIS is the leading tissue engineering company for body-own blood vessels.
The VACIS technology uses a synthetic rod which induces the formation of a new fully functional blood vessel providing novel therapeutic options for vascular surgery. Prosthetic vascular graft failure is a frequent complication in vascular surgery with substantial morbidity and health care costs. VACIS provides patients autologous graft vessels, with sustained patency and fewer complications requiring less corrective interventions.
Vascular grafts are needed in many areas of medicine. VACIS initially focuses on vascular access in patients undergoing hemodialysis. Other indications will follow after clinical validation of the technology in hemodialysis. Such other indications include peripheral arterial occlusive disease.
VACIS provides an advantage over other therapeutic options in the hemodialysis access market. Current solutions have a low patency: many arteriovascular fistulas fail to mature or no adequate vein is available; the foreign material in synthetic grafts lead to infection, stenosis, thrombosis etc. and the synthetic material does not heal after cannulation.